Stereoselective total syntheses of the four stereoisomeric forms of guaiacylglycerol 8-O-4′-coniferyl ether, viz., compounds 1, ent-1, 2, and ent-2, have been established. The key step involves an Evans/Seebach auxiliarycontrolled and syn-selective aldol process followed, in the reaction sequences leading to the anti-compounds, by a Mitsunobu reaction involving a benzylic alcohol residue. The proangiogenic properties of the synthetic materials were evaluated in a human microvascular endothelial cell tubule formation assay, thus revealing that they are all active, with the 8S-configured compounds 1 and 2 being the most potent.
■ INTRODUCTION
Compounds that promote the formation of new blood vessels from existing endothelia are described as proangiogenic and could be beneficial in promoting wound healing, treating burns, and the revascularization of ischemic tissues encountered in stroke victims and those suffering from cardiac disorders. 1 Screening plant extracts for such properties is an emerging area of interest and the rat aortic ring model and related assays have proven useful in identifying natural products that can modulate angiogenesis. 2, 3 By such means, various extracts of soybean (particularly the xylem sap) were evaluated recently, and two proangiogenic principals were isolated. 3 Although only small quantities of these materials were obtained, 1 H and 13 C NMR spectroscopic as well as mass spectral analyses suggested that these are one or other of the neolignans 1 or ent-1 and 2 or ent-2. 3 The racemic forms of these compounds have previously been isolated from various other plant sources and shown to exhibit a range of biological effects. 4 They are almost certainly produced in vivo through peroxidase-mediated radical coupling of coniferyl alcohol, and optically enriched forms of them (but of undefined absolute stereochemistry) have been generated by enzymatic dehydrogenative coupling of this monomer using cell-free extracts of a producing organism. 5 Given the very small amounts of these compounds available from natural sources, the seasonal variations in their yields, and the lack of information regarding their stereostructures (and, in many instances, their optical purities), unambiguous syntheses of the guaiacylglycerol 8-O-4′-coniferyl ethers 1, ent-1, 2, and ent-2 were sought in an effort to clarify matters. Herein, we detail the total syntheses of each of these four stereoisomeric 8-O-4′-linked neolignans 6, 7 and report on their proangiogenic properties ( Figure 1 ).
■ RESULTS AND DISCUSSION
Syntheses of the Racemic Forms of Compounds 1 and 2. Although many neolignans have been the subject of synthetic studies, 8 enantioselective approaches to 8-O-4′ linked systems, as required in accessing the compounds targeted here, have received only modest attention. 9, 10 Our first approach to compounds 1, ent-1, 2, and ent-2 is shown in Scheme 1, and in this we sought, inter alia, to exploit key elements of Ley's asymmetric synthesis of the 8-O-4′ neolignan polysphorin. 9a This started with the conversion, by conventional means, of commercially available ferulic acid (3) over four steps into bismethoxymethyl (MOM) ether 4 (79%) (see Experimental Section for details). Asymmetric dihydroxylation of the olefinic residue within compound 4 using AD-mix-α and methanesulfonamide afforded the diol 5 (78%), the configuration of which was assigned using the Sharpless "mnemonic". 11 Although the enantiomeric excess (ee) of this oxidation product was not established, the fact that it was optically active {[α] D + 10.7 (c = 1.02, CHCl 3 )} encouraged us to continue exploring the reaction sequence, the next step of which involved selective oxidation of the benzylic hydroxyl group within compound 5 using 2,3-dichloro-5,6-dicyano-1,4benzoquinone (DDQ) under ultrasonication conditions. 12 By such means, the acyloin 6 (86%) was obtained and the 
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Article DOI: 10.1021/acsomega.7b01459 ACS Omega 2017, 2, 7375−7388 associated hydroxyl group was reacted with p-toluenesulfonic anhydride in the presence of pyridine, thus giving the optically active ester 7 in 93% yield. Although treating this last compound with coniferyl aldehyde (8) in the presence of cesium carbonate and 18-crown-6 (18-C-6) led to the formation of the anticipated 8-O-4′-linked ether 9 (47%), this proved to be an optically inactive material, thus suggesting racemization of substrate 7 and/or the product had occurred under the reaction conditions. 1 Despite this, the completion of the synthetic pathway was pursued because of the capacity it provided to deliver the racemic forms of the target compounds (materials that would prove useful in establishing the enantiomeric excesses of their enantiomerically enriched congeners). So, compound 9 was treated with a trace of concentrated HCl in isopropanol, thus effecting cleavage of the MOM-ether residues, and thereby affording the dihydroxyderivative 10 (76%). The required 2-fold reduction of the ketoaldehyde 10 was best effected using polymer-supported borohydride 9a and, in a presumably sterically driven process, this gave a ca. 7:1 mixture of the diastereoisomeric syn-and anti-compounds (±)-1 and (±)-2, respectively, in 87% combined yield. These could be separated from one another using reverse phase high-performance liquid chromatography (HPLC) and the spectral data derived from each were in complete accord with those reported earlier 4e,l for the natural products (see Table 1 for relevant comparisons of the 13 C NMR data sets).
Although each of the synthetically derived compounds (±)-1 and (±)-2 could be separated into their constituent enantiomers using chiral HPLC techniques, the equivalent analysis of the soybean-derived natural products could not be carried out due to their decomposition on prolonged (>12 months) standing (as a crude extract). That said, when samples of these compounds have been isolated from other plant sources, they tend to be obtained as racemates or, at best, enantiomerically enriched (but certainly not homochiral) materials. 5a Chiral Auxiliary-Controlled Syntheses of Homochiral Compounds 1 and ent-1. The synthetic route successfully employed in obtaining neolignan ent-1 is shown in Scheme 2 and involved, as the key feature, an Evans' aldol reaction 13 utilizing the readily available L-valine (11)-derived chiral auxiliary 12 introduced by Seebach. 14 This was coupled with the eugenol (13)-derived and readily available α-aryloxyacetic acid 14 (85%) through its conversion into the corresponding acid chloride and reaction of this with the anion derived from deprotonation of the 2-oxazolidinone 12 using n-butyl lithium. Compound 15 (93%) so formed was then converted, on treatment with dibutylboron triflate in the presence of Hunig's base, 14a into the corresponding boron enolate that reacted stereoselectively with aldehyde 16 embodying a tert-butyldimethylsilyl (TBDMS)-protected phenol residue. The auxiliary associated with the aldol product so-formed was cleaved using lithium borohydride/methanol, thus affording the 1°-alcohol 17 (76% from 15) as a single diastereoisomer and in optically active form {[α] D = −63.3 (c = 0.8, CHCl 3 )}. The illustrated structure was initially assigned to compound 17 on the basis of the well-established syn-selective outcomes of Evans' aldol reactions 9h,13,14 involving the types of auxiliaries used here, but eventually it was confirmed through chemical correlation studies (see below). Aerobic and palladium-catalyzed acetoxylation of compound 17 using a procedure reported by Stahl et al. 15 and employing 4,5-diazafluorenone as ligand then afforded ester 18 in 48% yield and exclusively in the E-isomeric form. Cleavage of both the acetate and silyl ether residues associated with compound 18 was accomplished using potassium carbonate in methanol, thus giving the target neolignan ent-1 in 79% yield.
All of the mass spectral as well as the NMR and IR spectroscopic data acquired on compound ent-1 matched those derived from the corresponding racemate [(±)-1], and the specific rotation determined for the optically active material was −36.7 (c = 0.9, methanol). Chiral HPLC analysis of compound ent-1 established that it was of >99% enantiomeric excess and represents the less mobile component of the racemate (±)-1.
The synthesis of compound 1 was readily achieved following the reaction scheme shown above but using the auxilliary ent-12 derived from D-valine (ent-11) . Although all of the spectral data recorded on neolignan 1 matched those reported for its enantiomer, the specific rotation of this material was of similar magnitude but opposite sign {[α] D = +32.4 (c = 0.2, methanol)}. Chiral HPLC analysis of compound 1 established that it had been obtained in ca. 90% ee and represents the more mobile component of the racemate (±)-1 obtained earlier.
The synthesis of the anti-compound ent-2 is shown in Scheme 3 and involved, in the opening stages, selective monoprotection of the 1°-alcohol residue within compound 17 followed by cleavage of the associated phenolic TBDMS ether. This gave phenol 19 (96%) that was reacted with ptoluenesulfonyl chloride (p-TsCl) in the presence of triethyamine and 4-(N,N-dimethylamino)pyridine (DMAP) to afford ester 20 (87%). The introduction of the tosyl group was necessary to attenuate the electron-donating properties of the attached aryl oxygen such that this now did not facilitate ionization of activated forms of the benzylic alcohol during the subsequent Mitsunobu reaction. 16 Consistent with such expectations, when compound 20 was treated with triphenylphosphine and diethyl azodicarboxylate (DEAD), and using pnitrobenzoic acid as nucleophile, benzoate 21 (84%) was obtained. Confirmation of the illustrated S-configuration at the PNB-ester bearing center in this product follows from its conversion into the target neolignan ent-2. To such ends, treatment of compound 21 with sodium hydroxide in tetrahydrofuran (THF)/water afforded the alcohol 22 (74%) that was itself subjected to allylic oxidation using Stahl's protocol, 15 thereby affording acetate 23 in 64% yield.
Treatment of ester 23 with tetra-n-butylammonium fluoride (TBAF) then sodium hydroxide in water/methanol resulted in cleavage of the TBDMS ether, acetate, and tosyl groups such that the targeted neolignan ent-2 was obtained in 73% yield. All of the spectral data obtained on this material were consistent with the assigned structure. Chiral HPLC analysis established that it was of >99% ee. The specific rotation of this material was [α] 20 D = −8.1 (c = 1.1, methanol), and it represents the more mobile component of the racemate (±)-2.
The synthesis of compound 2 was readily achieved following the reaction scheme shown but using compound ent-17 as starting material. Although all of the spectral data recorded on neolignan 2 matched those reported for its enantiomer, the specific rotation of this material was of similar magnitude but opposite sign {[α] 20 D = +7.4 (c = 0.5, methanol)}. Similarly, chiral HPLC analysis of compound 2 established that it was of >99% ee and that it represents the less mobile component of the racemate (±)-2 obtained as described above.
To this point, the assignments of the illustrated structures to compounds 1, ent-1, 2, and ent-2 are based on the assumption that the pivotal Evans' aldol reactions proceed in the anticipated (syn-selective) manner and that the Mitsunobu reactions take place with inversion of configuration. Further support follows from the recent work of Nair et al., 9k who employed closely related Evans' aldol protocols to prepare compound 2 and who undertook certain chemical correlation studies and a single-crystal X-ray analysis to establish the selectivities of their pivotal reaction. The NMR spectroscopic data we acquired on compound 2 matched those reported by Nair. 9k Initial Biological Evaluations of Compounds 1, ent-1, 2, and ent-2. Compounds 1 and 2 as well as their enantiomers, ent-1 and ent-2, respectively, were each examined for their abilities to enhance endothelial cell tubule formation on reconstituted basement membrane matrix (see Figure 2 and the Experimental Section) in an assay widely used to identify proangiogenic and antiangiogenic factors and their underlying mechanism(s) of action. 17 All four compounds stimulated endothelial cell tubule formation compared with media only, with compounds 1 and 2 being the most active and congener ent-2 the least active. It is noteworthy that each of these neolignans exhibited significant proangiogenic activity compared with media only, with compound 1 being more active than the fibroblast growth factor 2 (FGF-2) control. 18 The flavone derivative PD98059, an inhibitor of mitogen-activated protein kinase (MEK1/2) and FGF-2 signaling, suppressed the proangiogenic activity of all of the compounds, which is consistent with the title neolignans acting via this pathway.
■ CONCLUSIONS
The work detailed here provides stereochemically unambiguous routes to a quartet of neolignans that display varying degrees of activity as proangiogenic agents. The variation in efficacy as a function of stereochemistry indicates that the S-configuration at C8 (as seen in neolignans 1 and 2) has a positive impact on activity, with compound 1 being even more active than the FGF-2 control. To the best of our knowledge, this work represents the first time that a suite of diastereisomerically related neolignans has been identified as proangiogenic agents. As such, it should serve as an important consideration for the development of proangiogenic compounds that might serve as therapeutic agents.
respectively. 1 H NMR data are recorded as follows: chemical shift (δ) [multiplicity, coupling constant(s) J (Hz), relative integral] where multiplicity is defined as: s = singlet; d = doublet; t = triplet; q = quartet; m = multiplet or combinations of the above. Infrared spectra (ν max ) were recorded on a Fourier transform infrared spectrometer. Samples were analyzed as thin films on KBr plates or as neat material. Low-resolution electrospray ionization (ESI) mass spectra were recorded on a single quadrupole liquid chromatograph-mass spectrometer, whereas high-resolution measurements were conducted on a time-of-flight instrument. Low-and high-resolution electron ionization (EI) mass spectra were recorded on a magneticsector machine. Melting points were measured on an Optimelt automated melting point system and are uncorrected. Analytical thin layer chromatography was performed on aluminum-backed 0.2 mm thick silica gel 60 F 254 plates as supplied by Merck. Eluted plates were visualized using a 254 nm UV lamp and/or by treatment with a suitable dip followed by heating. These dips included phosphomolybdic acid/ceric sulfate/sulfuric acid (conc.)/water (37.5 g:7.5 g:37.5 g:720 mL) or potassium permanganate/potassium carbonate/5% sodium hydroxide aqueous solution/water (3 g:20 g:5 mL:300 mL). Flash chromatographic separations were carried out following protocols defined by Still et al. 19 with silica gel 60 (40−63 μm) as the stationary phase and using the AR-or HPLC-grade solvents indicated. The melting points of solids purified by such means were recorded directly (i.e., after they had crystallized from the concentrated chromatographic fractions). Starting materials and reagents were generally available from the Sigma-Aldrich, Merck, TCI, Strem, or Lancaster Chemical Companies and were used as supplied. Drying agents and other inorganic salts were purchased from the AJAX, BDH, or Unilab Chemical Companies. Tetrahydrofuran (THF), methanol, and dichloromethane were dried using a Glass Contour solvent purification system that is based upon a technology originally described by Grubbs et al. 20 Where necessary, reactions were performed under a nitrogen atmosphere.
Specific Chemical Transformations. (E)-2-Methoxy-1-(methoxymethoxy)-4-(3-(methoxymethoxy)prop-1-en-1-yl)benzene (4).
Step i: Using a procedure analogous to that described by Bazin et al., 21 a magnetically stirred solution of ferulic acid (3) (30.2 g, 155.5 mmol) in dry methanol (200 mL) was treated with five drops of concentrated sulfuric acid, and the resulting mixture was heated under reflux for 24 h. The solution was then cooled to room temperature, and the solvent was removed under reduced pressure. The residue thus obtained was dissolved in dichloromethane, and the resulting solution was washed with NaHCO 3 (2 × 100 mL of a saturated aqueous solution) before being dried (MgSO 4 ), filtered, and concentrated under reduced pressure to afford a pale-yellow oil. 1, 146.9, 145.1, 127.1, 123.2, 115.3, 114.9, 109.5, 56.1, 51.7. These spectral data matched those reported by Li et al. 22 Step ii: Chloromethyl methyl ether (MOM-Cl) (12.0 mL, 158.3 mmol) was added dropwise to a magnetically stirred solution of ferulic acid methyl ester (22.0 g, 105.6 mmol) and Hunig's base (i-Pr 2 NEt) (27.6 mL, 158.3 mmol) in dry dichloromethane (100 mL) maintained at 0°C. The resulting mixture was allowed to warm to 22°C and stirred at this temperature for 14 h whilst being maintained under nitrogen then quenched with NH 4 Cl (50 mL of a saturated aqueous solution). The mixture thus obtained was stirred at 22°C for a further 1 h then treated with NaHCO 3 (100 mL of a saturated aqueous solution). The separated aqueous layer was extracted with ethyl acetate (3 × 100 mL) and the combined organic phases were washed with Na 2 CO 3 (3 × 50 mL of a saturated aqueous solution) and brine ( 7, 149.9, 148.6, 144.8, 128.8, 122.4, 116.2, 115.9, 110.4, 95.3, 56.5, 56.1, 51.8 . These spectral data matched those reported by Lui et al. 23 Step iii: Aluminum trichloride (14.45 g, 109.2 mmol) was added to dry THF (160 mL), and the resulting suspension was stirred at 0°C under nitrogen for 0.25 h. LiAlH 4 (150 mL of a 1 M solution in THF, 150 mmol) was then added dropwise over 0.5 h, and the resulting suspension was stirred for a further 0.5 h at 0°C. A solution of methyl (E)-3-(3-methoxy-4- Figure 2 . Effect of neolignans 1, ent-1, 2, and ent-2 on tubule formation by human microvascular endothelial cells (HMECs) on reconstituted basement membrane matrix (Matrigel) over a 4 h period compared with that of media (only) and fibroblast growth factor (FGF)-2 (positive) controls as well as when coadministered with the MEK1/2 inhibitor PD (PD98059). The columns represent the mean of the means of 4 independent experiments with each condition performed in triplicate. Error bars represent the standard error of the mean. Statistical significance was determined by one-way ANOVA and Dunnett's multiple comparisons test (compared with media only, i.e., MCDB131 medium with supplements and 0.2% fetal bovine serum (FBS)) using GraphPad Prism software, where **** denotes P < 0.0001, *** denotes P < 0.001, * denotes P < 0.05, ns denotes not significant, and † denotes significance at P < 0.01 between FGF-2 and compound 1. There was no significant difference between FGF-2 and compounds 2, ent-1, or ent-2.
(methoxymethoxy)phenyl)acrylate (24.97 g, 99 .0 mmol) in dry THF (20 mL) was then added (dropwise over 0.5 h) to the reaction mixture that was then stirred at 0°C for 0.5 h before being allowed to warm to 22°C and stirred for an additional 1 h at this temperature. The reaction mixture was then cooled to 0°C, water (5.7 mL) was added dropwise (Caution: hydrogen gas evolution), and stirring then continued for 0.25 h. After this time, NaOH (5.7 mL of a 15% w/v aqueous solution) was added to the reaction mixture, and stirring continued for an additional 0.25 h before more water (17.1 mL) was added. The resulting mixture was warmed to 22°C, diluted with Et 2 O (10 mL), then dried (MgSO 4 8, 146.4, 131.4, 131.1, 127.2, 119.7, 116.3, 109.5, 95.5, 63.9, 56.4, 56.0; IR ν max 3399, 2935 IR ν max 3399, , 1512 IR ν max 3399, , 1464 IR ν max 3399, , 1417 IR ν max 3399, , 1263 IR ν max 3399, , 1154 IR ν max 3399, , 1132 IR ν max 3399, , 1077 Step iv: MOM-Cl (10.7 mL, 141.3 mmol) was added dropwise to a magnetically stirred solution of (E)-3-(3methoxy-4-(methoxymethoxy)phenyl)prop-2-en-1-ol (21.18 g, 94.2 mmol) and Hunig's base (24.6 mL, 141.3 mmol) in dry dichloromethane (94 mL) maintained at 0°C under a nitrogen atmosphere. The resulting mixture was allowed to warm to 22°C and stirred at this temperature for 14 h before being quenched with NaHCO 3 (50 mL of a saturated aqueous solution). The mixture thus obtained was stirred for a further 1 h, then the organic layer was separated and washed with NaHCO 3 (1 × 50 mL of a saturated aqueous solution). The combined aqueous layers were extracted with ethyl acetate (3 × 100 mL), and then the combined organic phases were washed with NH 4 Cl (3 × 50 mL of a saturated aqueous solution), water (1 × 50 mL), and brine ( 8, 146.4, 132.6, 131.4, 124.2, 119.8, 116.3, 109.5, 95.7, 95.5, 68.0, 56.4, 56.0, 55.5; IR ν max 3375, 2934 IR ν max 3375, , 1512 IR ν max 3375, , 1464 IR ν max 3375, , 1265 IR ν max 3375, , 1152 IR ν max 3375, , 1133 IR ν max 3375, , 1102 IR ν max 3375, , 1078 IR ν max 3375, , 1036 (1R,2R)-1-(3-Methoxy-4-(methoxymethoxy)phenyl)-3-(methoxymethoxy)propane-1,2-diol (5). MeSO 2 NH 2 (856 mg, 9.0 mmol) was added to a magnetically stirred solution of AD-mix-α (12.48 g) in t-butanol/water (120 mL of a 1:1 v/v mixture) maintained at 22°C, and the resulting suspension was stirred for 0.5 h after which time both phases had become clear. This mixture was then cooled to 0°C before being treated with a solution of alkene 4 (2.00 g, 7.8 mmol) in t-butanol (2 mL). The reaction mixture thus obtained was stirred vigorously at 0°C for 72 h, quenched with Na 2 SO 3 (1.0 g), then allowed to warm to 22°C and stirred at this temperature 12 h. The resulting solution was concentrated under reduced pressure, and the residue thus obtained subjected to flash chromatography 4, 134.8, 119.4, 116.4, 110.3, 97.5, 95.6, 75.0, 74.7, 70.1, 56.4, 56.1, 55.8; IR ν max 3435, 2937 IR ν max 3435, , 1594 IR ν max 3435, , 1513 IR ν max 3435, , 1265 IR ν max 3435, , 1153 IR ν max 3435, , 1034 (R)-2-Hydroxy-1-(3-methoxy-4-(methoxymethoxy)phenyl)-3-(methoxymethoxy)propan-1-one (6) . DDQ (2.78 g, 12.25 mmol) was added to a magnetically stirred solution of diol 5 (1.79 g, 5.92 mmol) in dry benzene (30 mL) maintained under nitrogen at 22°C. The resulting suspension was sonicated for 5 h during which time the temperature of the water in the sonication bath was maintained between 22 and 30°C through the addition of ice. The reaction mixture thus obtained was cooled then filtered, and the filtrate was concentrated reduced pressure. The residue thus obtained was triturated with cold dichloromethane (4 × 10 mL), and the combined washings were filtered and the filtrate again concentrated under reduced pressure to afford a black oil. 8, 151.8, 150.0, 128.0, 123.1, 114.7, 111.4, 96.9, 95.2, 73.2, 71.1, 56.7, 56.3, 55.5; IR ν max 3444, 2937 IR ν max 3444, , 1676 IR ν max 3444, , 1595 IR ν max 3444, , 1512 IR ν max 3444, , 1464 IR ν max 3444, , 1266 IR ν max 3444, , 1148 IR ν max 3444, , 1115 IR ν max 3444, , 1080 IR ν max 3444, , 1032 (R)-1-(3-Methoxy-4-(methoxymethoxy)phenyl)-3-(methoxymethoxy)-1-oxopropan-2-yl 4-Methylbenzenesulfonate (7) . A magnetically stirred solution of alcohol 6 (1.52 g 5.06 mmol) in dry dichloromethane (20 mL) maintained under nitrogen was cooled to 0°C then treated with pyridine (600 μL, 7.59 mmol) and p-toluenesulfonic acid anhydride (2.48 g,
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Article DOI: 10.1021/acsomega.7b01459 ACS Omega 2017, 2, 7375−7388 7.6 mmol). The ensuing mixture was allowed to stir at 0°C for 0.5 h then warmed to 22°C and stirred at this temperature for an additional 1 h before being re-cooled to 0°C, quenched with pH 7 buffer (2 mL of a 1 M aqueous solution), then allowed to warm to 22°C. The mixture thus obtained was diluted with ethyl acetate (50 mL) before being washed with NH 4 Cl (1 × 40 mL) and brine (1 × 10 mL) The separated aqueous phase was extracted with ethyl acetate (3 × 20 mL), and the combined organic phases were washed with brine (3 × 20 mL) before being dried (MgSO 4 ), filtered, then concentrated under reduced pressure to afford an orange oil. This oil was subjected to flash chromatography (silica, dichloromethane 6, 151.7, 149.8, 145.2, 133.5, 129.8, 128.7, 128.2, 123.5, 114.6, 111.6, 96.7, 95.2, 79.8, 67.4, 56.7, 56.2, 55.6, 21.8; IR ν max 3374, 2940 IR ν max 3374, , 1690 IR ν max 3374, , 1595 IR ν max 3374, , 1512 IR ν max 3374, , 1464 IR ν max 3374, , 1421 IR ν max 3374, , 1364 IR ν max 3374, , 1267 IR ν max 3374, , 1176 IR ν max 3374, , 1079 IR ν max 3374, , 1030 5, 193.6, 152.6, 151.6, 150.2, 150.0, 149.8, 129.0, 128.5, 127.3, 123.4, 123.1, 115.5, 114.6, 111.7, 111.2, 96.9, 95.1, 81.7, 68.1, 56.7, 56.1(1) , 56.0 (7) (E)-3-(4-((3-Hydroxy-1-(4-hydroxy-3-methoxyphenyl)-1oxopropan-2-yl)oxy)-3-met-hoxyphenyl)acrylaldehyde (10). A magnetically stirred solution of aryl ether 9 (465 mg, 1.02 mmol) in dry isopropanol (30 mL) was treated with concentrated hydrochloric acid (3 drops), and the resulting solution was heated at 60°C for 22 h. The cooled reaction mixture was quenched with NaHCO 3 (20 mL of a saturated solution) then diluted with ethyl acetate (60 mL) before being washed with NaHCO 3 (2 × 20 mL). The separated aqueous phases were extracted with ethyl acetate (3 × 20 mL), and the combined organic phases were washed with brine ( 193.6, 152.4, 151.5, 150.5, 149.7, 147.1, 129.1, 127.6(2) , 127.5 (7), 124. 2, 123.1, 116.7, 114.3, 111.2, 110.7, 83.4, 63.9, 56.3, 56.1; IR ν max 3356, 2938 IR ν max 3356, , 1668 IR ν max 3356, , 1620 IR ν max 3356, , 1591 IR ν max 3356, , 1509 IR ν max 3356, , 1426 IR ν max 3356, , 1270 IR ν max 3356, , 1137 IR ν max 3356, , 1030 Compounds (±)-1 and (±)-2. Polymer-supported borohydride (2.5 mmol g −1 on Amberlite A-26, 400 mg, 1.0 mmol) was added in one portion to a magnetically stirred solution of compound 10 (77 mg, 0.21 mmol) in methanol (5 mL) maintained under nitrogen at 0°C. The ensuing mixture was stirred at this temperature for 4 h then allowed to warm to 22°C before being filtered, and the solids thus retained were washed with acetic acid in methanol (3 × 10 mL of a 1:99 v/v mixture). The combined filtrates were concentrated under reduced pressure to give a ca. 7:1 mixture of the title compounds (68 mg, 87%) as a light-yellow oil. Subjection of this material to preparative, reverse phase HPLC (Gemini C18 5μ 150 × 21.20 mm 2 column, 25:74.95:0.05 v/v/v/v methanol/ water/acetic acid elution, flow rate 17.0 mL/min) afforded two fractions, A and B.
Concentration of fraction A (t R = 12.0 min) afforded compound (±)-2 4e,10 (9 mg, 12%) as a white powder. 1 Concentration of fraction B (t R = 13.2 min) afforded compound (±)-1 4l,10 (57 mg, 73%) as a white powder. 1 Table 1 ; IR ν max 3369, 2931, 1604, 1510, 1263, 1129, 1079, 1029, 965 2-(4-Allyl-2-methoxyphenoxy)acetic Acid (14). Compound 14 was prepared in 85% overall yield from ethyl αbromoacetate and eugenol (13) 4, 149.9, 145.7, 137.2, 136.5, 121.3, 117.6, 116.3, 112.7, 69.0, 56.1, 40 .0. These spectral data matched those reported by Labarrios and co-workers. 26 (S)-3-(2-(4-Allyl-2-methoxyphenoxy)acetyl)-4-isopropyl-5,5-diphenyloxazolidin-2-one (15) . Oxalyl chloride (710 μL, 8.14 mmol) was added dropwise over 0.08 h to a magnetically stirred solution of carboxylic acid 14 (1.65 g, 7.40 mmol) and dimethylformamide (DMF) (28 μL, 0.37 mmol) in dichloromethane (15 mL) maintained at 0°C under a nitrogen atmosphere. The ensuing mixture was allowed to warm to 22°C and stirred until gas evolution ceased (ca. 1 h). The dichloromethane was then removed by sparging the reaction mixture with a stream of nitrogen followed by further concentration of the reaction mixture under reduced pressure. The acid chloride thus obtained was dissolved in dry THF (15 mL) . In a separate flask, n-BuLi (4.52 mL of a 1.5 M solution in hexanes, 6.79 mmol) was added dropwise over 0.25 h to a magnetically stirred solution of (S)-4-isopropyl-5,5-diphenyloxazolidin-2-one (12) 14b (1.74 g, 6.17 mmol) in dry THF (150 mL) maintained at 0°C. The resulting solution was stirred at this temperature for 0.5 h then cooled to −78°C. The previously formed solution of the acid chloride in THF was then added dropwise over 0.25 h, and stirring of the combined solutions continued at −78°C for 0.5 h. The cooling bath was then removed, and the reaction mixture was allowed to warm to 22°C and stirring was continued for 3 h. After this time, the reaction mixture was cooled to 0°C and quenched with NH 4 Cl (30 mL of a saturated aqueous solution) then acetic acid (5 mL). The ensuing mixture was allowed to warm, over 0.25 h, to 22°C then it was extracted with ethyl acetate (3 × 30 mL) . The combined organic phases were washed with NaHCO 3 (2 × 10 mL of a saturated aqueous solution) and brine (2 × 20 mL) before being dried (Na 2 2, 153.2, 149.4, 145.6, 142.1, 137.9, 137.7, 134.1, 129.2, 129.0, 128.6, 128.3, 126.0, 125.8, 120.4, 115.8, 113.6, 112.6, 91.1, 68.1, 64.9, 56.0, 40.0, 30.0, 21.9, 16.6; IR ν max 2969 IR ν max , 1780 IR ν max , 1724 IR ν max , 1510 IR ν max , 1257 IR ν max , 1209 IR ν max , 1178 IR ν max , 1147 IR ν max , 1035 (R)-3-(2-(4-Allyl-2-methoxyphenoxy)acetyl)-4-isopropyl-5,5-diphenyloxazolidin- 2-one (ent-15) . Compound ent-15 was prepared in an analogous fashion to that described immediately above from compounds ent-12 and 14. Flash chromatographic purification then gave oxazolidin-2-one ent-15 (8.79 g, quantitative yield) as a white foam, [α] 20 D = +160 (c = 0.3, CHCl 3 ). All the other spectral data acquired on this material were identical with those detailed above for compound 15.
(1R,2R)-2-(4-Allyl-2-methoxyphenoxy)-1-(4-((tertbutyldimethylsilyl)oxy)-3-methoxyphe-nyl)propane-1, 3-diol (17) .
Step i: A magnetically stirred solution of amide 15 (2.00 g, 4.12 mmol) in dry dichloromethane (8 mL) maintained at 0°C under a nitrogen atmosphere was treated, dropwise over 0.08 h, with freshly prepared 14b Bu 2 BOTf (1.07 mL, 1.35 g, 4.94 mmol) . The ensuing mixture was allowed to warm to 22°C, stirred at this temperature for 0.25 h, then freshly distilled Hunig's base (970 μL, 5.56 mmol) was added dropwise over 0.08 h. Stirring was continued at 22°C for another 0.5 h then the reaction mixture was cooled to −78°C before a solution of aldehyde 16 27 (1.35 g, 4.94 mmol) in dichloromethane (4 mL) was added via syringe pump over 0.75 h. The ensuing mixture was stirred at −78°C for a further 1 h then warmed to 0°C, stirred at this temperature for 4 h, then quenched with phosphate buffer (15 mL of a 1 M aqueous solution at pH 7) before being treated with methanol/30% aq. hydrogen peroxide (10 mL of a 1:1 v/v mixture) and allowed to warm to 22°C over 1 h. The biphasic mixture thus obtained was diluted with water (20 mL), and the separated aqueous layer was extracted with dichloromethane (3 × 10 mL). The combined organic phases were washed with brine (1 × 10 mL) then dried (Na 2 SO 4 ), filtered, and concentrated under reduced pressure. 3, 152.9, 150.7, 150.4, 145.5, 144.7, 141.6, 138.1, 137.5, 135.6, 131.9, 129.0(3) , 129.0(0), 128.5, 128. 1, 125.9, 125.4, 120.8, 120.5, 119.3, 118.5, 115.9, 113.1, 110.6, 90.1, 81.4, 74.0, 65.1, 56.0, 55.3, 40.0, 30.1, 25.9, 21.8, 18.6, 16.3, −4.5, −4.6; IR ν max 3452, 2954 IR ν max 3452, , 2930 IR ν max 3452, , 2858 IR ν max 3452, , 1777 IR ν max 3452, , 1716 IR ν max 3452, , 1510 IR ν max 3452, , 1450 IR ν max 3452, , 1369 IR ν max 3452, , 1283 IR ν max 3452, , 1210 IR ν max 3452, , 1153 IR ν max 3452, , 1035 Step ii: Methanol (230 μL, 5.65 mmol) was added to a magnetically stirred solution of the above-mentioned aldol product (1.70 g, 2.26 mmol) in THF (25 mL) maintained under nitrogen at 22°C. The resulting solution was cooled to 0°C , and lithium borohydride (123 mg, 5.65 mmol) was then added in portions over 0.08 h. The ensuing mixture was stirred at 0°C for 0.5 h then warmed to 22°C and stirred at this temperature for 2 h before being quenched with NH 4 Cl (20 mL of a saturated aqueous solution) then diluted with Et 2 O (100 mL). The separated aqueous layer was extracted with Et 2 O (2 × 20 mL), and the combined organic extracts were washed with brine (2 × 20 mL) then dried (Na 2 3, 151.2, 146.0, 145.1, 137.3, 136.5, 133.2, 121.7, 121.2, 119.8, 116.2, 112.6, 110.8, 90.0, 74.2, 61.3, 56.0, 55.6, 40.1, 25.9, 18.6, −4.5(0) , −4.5(2) (one signal obscured or overlapping); IR ν max 3453, 2954, 2931, 2857, 1510, 1465, 1419, 1283, 1264, 1228, 1156, 1034, 911, 840, 782 cm (1S,2S)-2-(4-Allyl-2-methoxyphenoxy)-1-(4-((tertbutyldimethylsilyl)oxy)-3-methoxyphen-yl)propane-1, 3-diol (ent-17) . Diol ent-17 was prepared as described immediately above from precursor ent-15 and aldehyde 16. Flash chromatographic purification of the product from step i gave the expected aldol product (2.15 g, 69%) as a clear, colorless oil, [α] 20 D = +77.7 (c = 1, CHCl 3 ). All the other spectral data acquired on this material were identical with those reported above for the product from step i. The conditions defined in step ii above were employed to produce diol ent-17 (684 mg, 96%), which was obtained as a clear, colorless oil, [α] 20 D = +66.2 (c = 0.7, CHCl 3 ). All other spectral data acquired on this material were identical with those reported above for compound 17.
(E)-3-(4-(((1R,2R)-1-(4-((tert-Butyldimethylsilyl)oxy)-3-methoxyphenyl)-1,3-dihydroxypr-oxypropan-2-yl)oxy)-3methoxyphenyl)allyl Acetate (18) . Acetic acid (370 μL, 6.5 mmol), sodium acetate (6.5 mg, 0.08 mmol), molecular sieves (2 mg of activated 4 Å material), 4,5-DAF (5.1 mg, 7 mol %), and Pd(OAc) 2 (6.3 mg, 7 mol %) were added sequentially to a magnetically stirred solution of compound 17 (190 mg, 0.40 mmol) in 1,4-dioxane (2.4 mL) maintained at 22°C. Oxygen from a balloon was bubbled through the resulting solution for 0.25 h, which was then heated to 60°C and maintained under an atmosphere of oxygen. After 48 h, the reaction mixture was cooled to 22°C, and the solvent was removed under reduced pressure. The black residue thus obtained was subjected to flash column chromatography (silica, hexane 151.4, 151.3, 147.9, 145.2, 133.8, 133.1, 132.6, 122.9, 121.0, 120.9, 120.5, 119.7, 110.8, 110.0, 89.7, 74.2, 65.1, 61.4, 56.1, 55.7, 25.9, 21.2, 18.6, −4.5(0), −4.5(2) ; IR ν max 3467, 2952, 2933, 2857, 1739, 1510, 1465, 1419, 1251, 1232, 1158, 1128, 1030, 908, 840 cm -18) . Allylic oxidation of compound ent-17 in the same manner as that described above for congener 17 afforded, after flash chromatographic purification, compound ent-18 (71 mg, 65%) as a pale-yellow oil, [α] 20 D = +47.5 (c = 1.6, CHCl 3 ). All other spectral data acquired on this material were identical with those reported above for compound 18.
(1R,2R)-1-(4-Hydroxy-3-methoxyphenyl)-2-(4-((E)-3-hydroxyprop-1-en-1-yl)-2-methox-yphenoxy)propane-1,3-diol (ent-1). K 2 CO 3 (270 mg, 1.95 mmol) was added to a magnetically stirred solution of acetate 18 (45 mg, 0.085 mmol) in methanol (5 mL) containing water (100 μL) and maintained at 22°C under a nitrogen atmosphere. The ensuing mixture was stirred at this temperature for 18 h then diluted with ethyl acetate (20 mL), acidified (to pH 5) using acetic acid (ca. 200 μL), then washed with water (1 × 5 mL) and brine (2 × 5 mL) before being dried (Na 2 SO 4 ), filtered, and concentrated under reduced pressure. The ensuing pale-yellow oil was subjected to flash column chromatography (silica, 1:19 v/v methanol/dichloromethane → 1:9 v/v methanol/dichloromethane gradient elution). Concentration of the appropriate fractions (R f = 0. 3.47 (dd, J = 11.9 and 5.4 Hz, 1H) (signals due to hydroxyl group protons not observed); 13 C NMR (100 MHz, CD 3 OD) δ 151. 8, 149.2, 148.8, 147.2, 133.8, 133.1, 131.4, 128.6, 120.8, 120.7, 118.8, 115.8, 111.7, 111.3, 87.1, 74.0, 63.8, 61.9, 56.5, 56.3; IR ν max 3348, 2934 IR ν max 3348, , 1602 IR ν max 3348, , 1509 IR ν max 3348, , 1464 IR ν max 3348, , 1263 IR ν max 3348, , 1226 IR ν max 3348, , 1156 IR ν max 3348, , 1130 IR ν max 3348, , 1027 (1S,2S)-1-(4-Hydroxy-3-methoxyphenyl)-2-(4-((E)-3-hydroxyprop-1-en-1-yl)-2-methoxy-phenoxy)propane-1, 3-diol (1) . Treatment of acetate ent-18 with potassium carbonate in the same manner as that described above gave neolignan 1 (28 mg, 93%) as a clear, colorless gum, [α] 20 D = +32.4 (c = 0.2, methanol). All other spectral data acquired on this material were identical with those reported above for compound ent-1. HPLC analysis: Trefoil CEL1 column, 98:2 v/v methanol/ supercritical CO 2 elution, flow rate 2 mL/min, temperature 40°C
, detection at λ = 254 nm, t minor = 5.86 min, t major = 6.05 min, ee = 90%.
4-((1R,2R)-2-(4-Allyl-2-methoxyphenoxy)-3-((tertbutyldimethylsilyl)oxy)-1-hydroxyprop-yl)-2-methoxyphenol (19) . The following one-pot procedure for preparing compound 19 was established after that used to prepare its enantiomer (ent-19) and proved to be the more efficient one. Thus, a magnetically stirred solution of diol 17 (565 mg, 1.19 mmol) in DMF (4 mL) was cooled to 0°C and treated sequentially with imidazole (162 mg, 2.38 mmol) and 1.25 mmol) . The ice bath was then removed, and the resulting solution was stirred at 22°C for 1.5 h before being treated with Cs 2 CO 3 (774 mg, 3.38 mmol) and water (400 μL). The resulting mixture was stirred at 22°C for 2 h then heated at 40°C for 4 h. The cooled reaction mixture was stirred at 22°C for 16 h before being diluted with ethyl acetate (30 mL) and washed with NH 4 Cl (3 × 10 mL of a saturated aqueous solution). The combined aqueous phases were extracted with ethyl acetate (3 × 10 mL) and the combined organic phases washed with brine (2 × 10 mL) then dried (Na 2 SO 4 ), filtered, and concentrated under reduced pressure. The resulting paleyellow residue was subjected to flash column chromatography (silica, 7, 147.0, 146.6, 145.5, 137.6, 135.4, 132.4, 121.1, 120.6, 120.3, 116.0, 114.2, 112.4, 109.6, 89.0, 74.0, 62.7, 56.1, 55.9, 40.1, 26.0, 18.5, −5.3(0), −5.3(4) ; IR ν max 3466, 2954, 2930, 2856, 1606, 1509, 1454, 1266, 1227, 1127, 1035, 836, 779 4-((1S,2S)-2-(4-Allyl-2-methoxyphenoxy)-3-((tertbutyldimethylsilyl)oxy)-1-hydroxypropy-l)-2-methoxyphenol (ent-19) . A magnetically stirred solution of diol ent-17 (452 mg, 0.95 mmol) in dichloromethane (6 mL) was cooled to −5°C and treated sequentially with imidazole (129 mg, 1.9 mmol) and TBDMS-Cl (155 mg, 1.00 mmol). The cooling bath was then removed, and the reaction mixture was stirred at 22°C for 16 h before being quenched with NH 4 Cl (10 mL of a saturated aqueous solution). The separated aqueous phase was extracted with dichloromethane (3 × 10 mL) and the combined organic phases were then washed with brine (2 × 10 mL) before being dried (Na 2 SO 4 ), filtered, and concentrated under reduced pressure to give the anticipated bis-TBDMS ether (386 mg) as a light-yellow oil. This oil was dissolved in DMF (1 mL), and the resulting solution was treated with Cs 2 CO 3 (307 mg, 0.95 mmol) and water (100 μL) then stirred at 22°C for 24 h. After this time, another batch of Cs 2 CO 3 (200 mg, 0.62 mmol) was added, and stirring continued for an additional 24 h. The reaction mixture was then diluted with ethyl acetate (30 mL) before being washed with NH 4 Cl (3 × 10 mL of a saturated aqueous solution). The combined aqueous washings were extracted with ethyl acetate (3 × 10 mL), and the combined organic phases were then washed with brine (2 × 10 mL) before being dried (Na 2 SO 4 ), filtered, and concentrated under reduced pressure. The ensuing pale-yellow residue was subjected to flash column chromatography (silica, 1:9 v/v Et 2 O/dichloromethane), and concentration of the appropriate fractions (R f = 0.2 in 1:19 v/v Et 2 O /DCM) afforded phenol ent-19 (232 mg, 51% over two steps) as a clear, colorless oil, [α] 20 D = +98.8 (c = 0.7, CHCl 3 ). All other spectral data acquired on this material were identical with those reported above for compound 19.
4-((1R,2R)-2-(4-Allyl-2-methoxyphenoxy)-3-((tertbutyldimethylsilyl)oxy)-1-hydroxyprop-yl)-2-methoxyphenyl . p-Toluenesulfonyl chloride (216 mg, 1.13 mmol) was added in one portion to a magnetically stirred solution of phenol 19 (512 mg, 1.08 mmol) and triethylamine (225 μL, 1.62 mmol) in dichloromethane (50 mL) maintained at 0°C. DMAP (6.6 mg, 0.05 mmol) was then added to the reaction mixture, and stirring was continued at 0°C for 1 h. The resulting mixture was quenched with NH 4 Cl (20 mL of an aqueous solution), and the separated aqueous layer was extracted with dichloromethane (2 × 10 mL). The combined organic phases were washed with brine (2 × 15 mL) before being dried ( 6, 150.6, 146.4, 144.9, 140.7, 137.8, 137.3, 135.6, 133.2, 129.3, 128.7, 123.6, 121.0, 120.0, 119.3, 115.9, 112.4, 111.3, 87.8, 73.4, 62.3, 55.7, 55.5, 39.9, 25.9, 21.7, 18.3, −5 .5 (one signal obscured or overlapping); IR ν max 3475, 2951, 2931, 2856, 1600, 1506, 1464, 1419, 1264, 1176, 1092, 1035, 837, 779 (E)-3-(4-(((1R,2S)-3-((tert-Butyldimethylsilyl)oxy)-1-hydroxy-1-(3-methoxy-4-(tosyloxy)-phenyl)propan-2-yl)oxy)-3methoxyphenyl)allyl Acetate (ent-23). Oxidation of alkene ent-22 in an analogous fashion to that described immediately above gave acetate ent-23 (67 mg, 33%) as a clear, colorless oil, [α] 20 D = +17.7 (c = 1, CHCl 3 ). All other spectral data acquired on this material were identical with those reported above for compound 23.
(1S,2R)-1-(4-Hydroxy-3-methoxyphenyl)-2-(4-((E)-3-hydroxyprop-1-en-1-yl)-2-methoxyp-henoxy)propane-1, 3-diol (ent-2) . TBAF·xH 2 O (37 mg, ca. 0.12 mmol) was added in one portion to a magnetically stirred solution of acetate 23 (55 mg, 0.080 mmol) in THF (3 mL) maintained at 22°C under a nitrogen atmosphere. After 1 h, the reaction mixture was treated with methanol (3 mL) then NaOH (1 mL of a 3 M aqueous solution, 3 mmol) before being heated at 80°C. After 3 h, the reaction mixture was cooled to 22°C, acidified to pH 5 using acetic acid, then diluted with ethyl acetate (15 mL) . The separated organic phase was washed with brine (3 × 5 mL of a ca. 13 wt % solution), and the combined aqueous washings were extracted with ethyl acetate (3 × 5 mL). The combined organic phases were washed with brine (1 × 5 mL of a ca. 13 wt % solution) before being dried (Na 2 SO 4 ), filtered, and concentrated under reduced pressure. The ensuing pale-yellow residue was subjected to flash column chromatography (silica, 1:19 v/v methanol/dichloromethane → 1:9 v/v methanol/ dichloromethane gradient elution), and concentration of the appropriate fractions (R f = 0.5 in 1:9 v/v methanol/dichloromethane) afforded compound ent-2 (22 mg, 73%) as a clear, colorless gum, [α] 20 D = −8.2 (c = 1.1, methanol). 1 H NMR (400 MHz, CD 3 OD) δ 7.02 (d, J = 1.9 Hz, 1H), 6.99 (broad s, 1H), 6.88−6.86 (complex m, 2H), 6.84 (dd, J = 8.1 and 1.9 Hz, 1H), 6.73 (d, J = 8.1 Hz, 1H), 6.51 (dt, J = 15.9 and 1.5 Hz, 1H), 6.23 (dt, J = 15.8 and 5.8 Hz, 1H) 9, 148.9, 148.7, 147.0, 134.1, 133.0, 131.4, 128.5, 121.0, 120.6, 118.9, 115.6, 111.9, 111.4, 86.2, 74.1, 63.7, 62.2, 56.5, 56.3; IR ν max 3345, 2937 IR ν max 3345, , 1602 IR ν max 3345, , 1509 IR ν max 3345, , 1463 IR ν max 3345, , 1264 IR ν max 3345, , 1128 IR ν max 3345, , 1028 (1R,2S)-1-(4-Hydroxy-3-methoxyphenyl)-2-(4-((E)-3-hydroxyprop-1-en-1-yl)-2-methoxyp-henoxy)propane-1,3-diol (2) . Treatment of compound ent-23 with TBAF then aqueous sodium hydroxide in an analogous fashion to that described immediately above gave compound 2 9k (6.8 mg, 73%) as a clear, colorless gum, 6, 147.4, 146.8, 145.3, 133.0, 129.9, 128.4, 128.3, 119.3, 118.8, 115.5, 114.4, 111.3, 109.8, 83.6, 71.5, 61.4, 60.0, 55.5, 55.3 . These spectral data matched those reported by Nair and co-workers. 9k All other spectral data acquired on this material were identical with those reported above for compound ent-2. HPLC analysis: Chiracel AS-H column, 85:15 v/v n-hexane/ethanol elution, flow rate 1.0 mL/min, detection at λ = 254 nm, t = 43.2 min, ee > 99%.
Endothelial Cell Tubule Formation Assay. Human microvascular endothelial cells (HMECs) were grown in MCDB131 media supplemented with 10% fetal bovine serum (FBS), hydrocortisone (500 μg/mL), epidermal growth factor (0.01 mg/mL), L-glutamine (2 mM), and antibiotics. At 80− 90% confluency, the cells were trypsinized, pelleted by centrifugation, and resuspended in MCDB131 medium containing 0.2% FBS at 4 × 10 5 /mL cell density. One mL of the cell suspension was then transferred to microfuge tubes and incubated with 30 μM PD98059 for 0.5 h at room temperature prior to the addition of 12.5 ng/mL FGF-2 or 0.1 μM of each of the compounds 1, ent-1, 2, and ent-2 (final concentrations). Alternately, 1 mL of cell suspension was incubated with FGF-2 alone (12.5 ng/mL) or each neolignan (0.1 μM). The suspensions were gently mixed (pipetting up and down three times), and 100 μL (4 × 10 4 cells) was aliquoted into a 96 well plate that had been pre-coated overnight at 4°C with Matrigel basement membrane matrix. The plates were incubated at 37°C
, and the cells in each well were photographed (under 40× magnification) 4 h after seeding. Microtubules were counted using Image J software. Each treatment was performed in triplicate, and four independent experiments were performed.
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